Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
With the rapidly rising incidence of Type 2 diabetes and an increasing variety of medications available for treatment, choosing the ideal regimen for patients can be challenging. Longer-acting glucagon-like peptide-1 (GLP-1) receptor agonists and devices have been recently developed and include once-weekly exenatide, dulaglutide, albiglutide, semaglutide and miniosmotic pump ITCA650. Some of the attractive qualities of the GLP-1 receptor agonist class include its association with weightloss and potential for cardiovascular benefits. The longer-acting forms have been shown in several studies to produce equal or greater reduction in A1c and weight compared with the standard twice-daily formulation of exenatide. They also result in lower reported incidence of nausea, in the setting of a less frequent injection schedule that would be desirable to many diabetic patients. There are emerging data to suggest patients treated with longer-acting GLP-1 receptor agonists have improved cardiac parameters, some of which are independent of weight and A1c reductions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Self-citationType 2 diabetes among North adolescents: An epidemiologic health perspective
Fagot-Campagna, A., Pettitt, D. J., Engelgau, M. M., Burrows, N. R., Geiss, L. S., Valdez, R., Beckles, G. L. A., Saaddine, J., Gregg, E. W., Williamson, D. F., et al. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.105141 · Cited by 1,285
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Research works printed but not linked: 44
- Shaw, 2010, Diabetes Res. Clin. Pract., 87, 4, 10.1016/j.diabres.2009.10.007 · DOI · Paper page
- Mokdad, 2003, JAMA, 289, 76, 10.1001/jama.289.1.76 · DOI · Paper page
- Drucker, 2006, Lancet, 368, 1696, 10.1016/S0140-6736(06)69705-5 · DOI · Paper page
- Holst, 2008, Trends Mol. Med., 14, 161, 10.1016/j.molmed.2008.01.003 · DOI · Paper page
- Robles, 2009, Drug Des. Devel. Ther., 3, 219, 10.2147/DDDT.S3321 · DOI
- Chia, 2008, J. Clin. Endocrinol. Metab., 93, 3703, 10.1210/jc.2007-2109 · DOI · Paper page
- Montanya, 2009, Clin. Ther., 31, 2472, 10.1016/j.clinthera.2009.11.034 · DOI
- 10.2337/dc06-2375 · DOI · Paper page
- Buse, 2010, Diabetes Care, 33, 1255, 10.2337/dc09-1914 · DOI · Paper page
- Bergenstal, 2010, Lancet, 376, 431, 10.1016/S0140-6736(10)60590-9 · DOI · Paper page
- Wysham, 2011, Diabet. Med., 28, 705, 10.1111/j.1464-5491.2011.03301.x · DOI · Paper page
- Russell-Jones, 2012, Diabetes Care, 35, 252, 10.2337/dc11-1107 · DOI · Paper page
- Rosenstock, 2009, Diabetes Care, 32, 1880, 10.2337/dc09-0366 · DOI · Paper page
- Glaesner, 2010, Diabetes Metab. Res. Rev., 26, 287, 10.1002/dmrr.1080 · DOI · Paper page
- Toft-Nielsen, 1999, Diabetes Care, 22, 1137, 10.2337/diacare.22.7.1137 · DOI · Paper page
- Davies, 2012, Diabetes Obes. Metab., 14, 882, 10.1111/j.1463-1326.2012.01595.x · DOI · Paper page
- Minze, 2011, J. Fam. Pract., 60, 577
- Aroda, 2011, Postgrad. Med., 123, 228, 10.3810/pgm.2011.09.2479 · DOI · Paper page
- Buse, 2013, Lancet, 381, 117, 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
- Aroda, 2012, Clin. Ther., 34, 1247.e22, 10.1016/j.clinthera.2012.04.013 · DOI · Paper page
- Best, 2009, Diabet. Med., 26, 722, 10.1111/j.1464-5491.2009.02752.x · DOI · Paper page
- Tomkin, 2009, Curr. Opin. Mol. Ther., 11, 579
- Bush, 2009, Diabetes. Obes. Metab., 11, 498, 10.1111/j.1463-1326.2008.00992.x · DOI · Paper page
- Rosenstock, 2010, Drugs Fut, 35, 701, 10.1358/dof.2010.035.09.1516042 · DOI
- Barrington, 2011, Diabetes. Obes. Metab., 13, 434, 10.1111/j.1463-1326.2011.01365.x · DOI · Paper page
- Umpierrez, 2011, Diabetes. Obes. Metab., 13, 418, 10.1111/j.1463-1326.2011.01366.x · DOI · Paper page
- Raz, 2012, Diabetes Care, 35, 485, 10.2337/dc11-1942 · DOI · Paper page
- Fineman, 2012, Diabetes. Obes. Metab., 14, 546, 10.1111/j.1463-1326.2012.01561.x · DOI · Paper page
- Blonde, 2009, Diabetes. Obes. Metab., 11, 26, 10.1111/j.1463-1326.2009.01075.x · DOI · Paper page
- Ratner, 2011, Cardiovasc. Diabetol., 10, 22, 10.1186/1475-2840-10-22 · DOI · Paper page
- Haffner, 1998, N. Engl. J. Med., 339, 229, 10.1056/NEJM199807233390404 · DOI · Paper page
- 10.2337/diabetes.54.1.146 · DOI · Paper page
- Sivertsen, 2012, Nat. Rev. Cardiol., 9, 209, 10.1038/nrcardio.2011.211 · DOI
- Kavianipour, 2003, Peptides, 24, 569, 10.1016/S0196-9781(03)00108-6 · DOI
- Nikolaidis, 2004, Circulation, 110, 955, 10.1161/01.CIR.0000139339.85840.DD · DOI · Paper page
- 10.3132/dvdr.2004.005 · DOI · Paper page
- Bao, 2011, PLoS ONE, 6, e23570, 10.1371/journal.pone.0023570 · DOI · Paper page
- Best, 2011, Diabetes Care, 34, 90, 10.2337/dc10-1393 · DOI · Paper page
- Monami, 2011, Exp. Diabetes Res., 2011, 215764
- Okerson, 2012, Cardiovasc. Ther., 30, e146, 10.1111/j.1755-5922.2010.00256.x · DOI · Paper page
- Robinson, 2013, Br. Med. J., 3
- Singh, 2013, JAMA Intern. Med., 25, 1
- Guillermin, 2012, J. Med. Econ., 15, 654, 10.3111/13696998.2012.670677 · DOI
- Gaebler, 2012, Vasc. Health Risk Manag., 8, 255, 10.2147/VHRM.S28744 · DOI
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
“When the results from these trials are available, there will be more definitive answers on the relationship between GLP-1 receptor agonists and cardiovascular safety [73].”
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“Indeed, several ongoing studies are evaluating the longer-term effects of GLP-1 receptor agonists on cardiovascular outcomes (69), including lixisenatide (ELIXA study), liraglutide 1.”
BackgroundHeuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
Treatment of type 2 diabetes with the designer cytokine IC7Fc
Findeisen, M., Allen, T. L., Henstridge, D. C., Kammoun, H., Brandon, A. E., Baggio, L. L., Watt, K. I., Pal, M., Cron, L., Estevez, E., et al. (2019) · Nature · doi:10.1038/s41586-019-1601-9 · Cited by 86
Metadata
- Authors
- Tibble, C. A., Cavaiola, T. S., & Henry, R. R.
- Venue
- Expert Review of Endocrinology & Metabolism
- Publisher
- Informa UK Limited
- Published
- 2013-05
- Volume
- 8
- Issue
- 3
- Pages
- 247-259
- ISSN
- 1744-6651 (ISSN-L)
- 1744-8417
- OpenAlex
- W2105554519
- Cited by
- 25
- References
- 19
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.